Encode functional p53
Compare p53 coding-sequence designs and RNA versus DNA formats. Sequence optimization is intended to support expression while preserving the desired protein; it does not establish biological activity.
Division 02 / Active oncology development
Our origin.
An active research program.
Wright Health began with p53, the “guardian of the genome.” Our gene-therapy research program is transitioning from in silico design toward pre-clinical validation, with the long-term goal of progressing from lab bench to bedside.
We are designing a p53-encoding RNA/DNA expression system alongside an optimized delivery vehicle. Targeted administration and controllable expression are central design objectives; the payload format and delivery route remain under evaluation.
CURRENT TRANSITION / IN SILICO → PRE-CLINICAL VALIDATION
Why p53 matters
The guardian
of the genome.
The TP53 gene encodes p53, a tumor-suppressor protein that helps cells respond to DNA damage through cell-cycle control, repair and, when appropriate, programmed cell death.
Loss of normal p53 function can enable damaged cells to survive and proliferate, contributing to cancer. TP53 is mutated in about half of human cancers; the frequency varies by tumor type, and the pathway can also be impaired through other mechanisms.
NIH MedlinePlus / TP53 biology and cancer ↗The development objective
Investigating restoration
of tumor suppression.
The immediate goal is to evaluate whether a p53-encoding expression vector or payload—RNA or DNA, to be determined—can be delivered and expressed to produce the intended biological response in relevant cell models.
We are investigating gene therapy intended to restore functional p53 expression. Construct architecture, targeted delivery and control of expression are the core engineering questions. Tumor selectivity, dosing, tolerability and efficacy must be established through pre-clinical validation.
Proposed architecture / Under evaluation
One therapeutic idea.
Three connected design decisions.
Our whitepaper frames a p53 coding payload, an expression-control system and a delivery vehicle as an integrated development problem.
These are design concepts to evaluate, with performance to be established experimentally.
Evaluate location, level and duration
For DNA-based designs, assess transcriptional control and tumor-responsive regulatory elements. For RNA-based designs, assess RNA stability and translational control. Controllable expression and targeting remain objectives to test, rather than established capabilities.
Match the payload to the route
Lipid nanoparticles are a delivery approach discussed in the whitepaper. Evaluate payload protection, cellular uptake and intracellular release alongside candidate targeting strategies and local versus systemic administration. Final vehicle and route selection depend on the evidence.
Published foundations / Independent of Wright Health
The rationale in the literature.
These publications explain the research context. Wright Health did not conduct these studies; its own candidates require separate evaluation.
The scale of TP53 disruption in cancer
Donehower and colleagues analyzed TCGA data across 32 cancer types. More than 91% of TP53-mutant cancers in their analysis also showed loss of the second allele through mutation, deletion or copy-neutral loss of heterozygosity.
What this does and does not establish
Donehower et al. / Cell Reports / 2019 ↗The 91% figure refers to the TP53-mutant subset, not all cancers. This observational analysis describes cancer biology; it does not demonstrate that gene replacement will benefit a patient.
Restoring p53 function in established tumors
Ventura and colleagues reported tumor regression following controlled restoration of endogenous p53. Responses differed by tumor type: apoptosis in lymphomas and growth suppression with senescence features in sarcomas.
What this does and does not establish
Ventura et al. / Nature / 2007 ↗This establishes a rationale in particular mouse models. It does not validate Wright Health's construct or delivery system, or demonstrate efficacy in humans.
Senescence and tumor clearance
Xue and colleagues reported that p53 restoration triggered senescence and an immune-associated tumor-clearance response in a mouse liver-cancer model.
What this does and does not establish
Xue et al. / Nature / 2007 ↗The response was model-dependent. It is not evidence of a universal cancer-cell kill switch or a demonstrated outcome for a Wright Health candidate.
Wright Health / Experimental program
From bioinformatic iterations to testable questions.
An experimental design informed by iterative computational review is the starting asset. The next step is pre-clinical evaluation of p53 expression/delivery candidates, beginning in cell models.
Compare p53 expression/delivery candidates
Use literature and bioinformatic review to examine p53 coding sequences, RNA/DNA architecture, delivery assumptions and expression-control requirements. Computational predictions guide prioritization; laboratory work must test them.
Define the experiment before execution
Specify relevant cancer and nonmalignant cell models, vehicle-only and untreated controls, comparators and measurements. Write the criteria for advancing or revising p53 expression/delivery candidates before interpreting the results.
Evaluate expression and biological response
For each p53 expression/delivery candidate, assess uptake, p53 protein expression and localization, and downstream responses such as p21 pathway activation, cell-cycle changes or apoptosis. Compare cancer and nonmalignant cells and test reproducibility; these are planned readouts, not reported results.
Refine, advance or stop
Review p53 expression/delivery candidate performance and limitations alongside delivery feasibility, manufacturing requirements and IP assessment. Progress to appropriate in vivo models only where cell-based evidence and ethical review justify the next studies.
The route forward
From design to clinical readiness.
An active development sequence with evidence gates. These stages describe planned progression; they do not imply completed studies or a scheduled clinical trial.
- 01IN SILICOCurrent transition
Expression-vector & delivery design
Compare p53 coding sequences, RNA/DNA payload architectures, expression-control strategies and candidate delivery systems. Define the experimental questions and assays needed for pre-clinical validation.
- 02PRE-CLINICAL / IN VITRONext evidence gate
Cell-based validation
Evaluate p53 expression/delivery candidates for delivery efficiency, expression level and duration, downstream biological activity and initial safety signals in relevant cancer and nonmalignant cell models. Iterate the design from the results.
- 03PRE-CLINICAL / IN VIVOConditional on cell data
Broader proof of concept
Use appropriate in vivo models to evaluate distribution, activity, dosing and safety. Select further studies according to the p53 expression/delivery candidate and intended indication, with appropriate ethical review.
- 04REGULATORYConditional on maturity
Clinical preparation
Develop manufacturing and quality controls, assemble the supporting nonclinical evidence and engage regulators on a proposed clinical development plan.
- 05CLINICALFuture development goal
Potential first-in-human study
Seek clinical entry only when the evidence, manufacturing readiness, regulatory requirements and ethical approvals support a trial.
No Wright Health oncology candidate has established clinical safety or efficacy. In vitro results alone do not establish clinical readiness. Any U.S. human gene-therapy study would require an IND and appropriate regulatory and ethics review.
FDA: gene therapy development ↗